Former GSK execs get $3.2M for research on a possible diabetes drug
A small Research Triangle Park company seeking to find next-generation drugs, received two federal grants totaling $3.2 million, an amount that will nearly triple the total the company has raised to date.
NovaTarg – owned and led by former GlaxoSmithKline executives – will use the money to continue research on potential drug candidates for polycystic kidney disease and type 2 diabetes during this coming year.
Diabetes is a potentially huge market, with some analysts estimating that even just… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news
Medical News Today: New drug delivery system may open up treatments for polycystic kidney disease
A new method that allows antibodies to penetrate cyst walls may open the door for already approved drugs to target the growth factors that drive polycystic kidney disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2015 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Delivering drugs to the right place
For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon. A targeted drug delivery method has been developed that could potentially slow the progression of polycystic kidney disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 25, 2015 Category: Science Source Type: news
New treatment for polycystic kidney disease
(University of Manchester) A new technique for treating polycystic kidney disease has been identified by researchers at The University of Manchester and UCL. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2015 Category: Global & Universal Source Type: news
New treatment for polycystic kidney disease
A new technique for treating polycystic kidney disease has been identified by researchers. Polycystic kidney disease (PKD) is a genetic disorder where fluid filled cysts grow in kidneys and destroy normal renal tissue. It is the world's most common inherited kidney disease, affecting between 1 in 400 and 1 in 1000 people worldwide -- around 12.5 million individuals. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 2, 2015 Category: Science Source Type: news
Tolvaptan (Jinarc) Cleared in Europe for Rare Kidney DiseaseTolvaptan (Jinarc) Cleared in Europe for Rare Kidney Disease
The vasopressin-2 receptor antagonist is the first drug to be licensed in Europe for the treatment of the underlying pathophysiology of autosomal dominant polycystic kidney disease. International Approvals (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - May 27, 2015 Category: Nursing Tags: Nephrology News Alert Source Type: news
Indian man's kidneys grew to size of a baby due to genetic disease
The man, who was treated at a hospital in Delhi, was suffering from autosomal dominant polycystic kidney disease, a genetic condition that caused his organs to grow to 20 times their normal size. (Source: the Mail online | Health)
Source: the Mail online | Health - April 22, 2015 Category: Consumer Health News Source Type: news
Jinarc (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jinarc (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD). (Source: Drug Development Technology)
Source: Drug Development Technology - March 19, 2015 Category: Pharmaceuticals Source Type: news
CHMP Backs Tolvaptan (Jinarc) for Rare Kidney DiseaseCHMP Backs Tolvaptan (Jinarc) for Rare Kidney Disease
Tolvaptan, a vasopressin-2-receptor antagonist that slows cyst formation, would be the first drug specifically approved in the European Union for autosomal dominant polycystic kidney disease. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news
Expert panel recommends new approaches to management of ADPKD
A report has been published by the European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, as well as patient group representatives, dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD) – a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 30, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Practical therapeutics Nephrology Patient care Autosomal dominant polycystic kidney disease cysts EAF economic impact hypertension Latest News Source Type: news
No Help From Dual RAAS Blockade in PKD (CME/CE)
(MedPage Today) -- No benefit to combining ACE inhibitor with ARB in polycystic kidney disease. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
Dual RAAS Blockade No Better Than ACE Inhibitor to Slow PKDDual RAAS Blockade No Better Than ACE Inhibitor to Slow PKD
In early or moderate autosomal dominant polycystic kidney disease, dual RAAS blockade did not slow the long-term decline in kidney function when compared with an ACE inhibitor alone. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2014 Category: Consumer Health News Tags: Nephrology News Source Type: news
Two drugs are no more effective than 1 to treat common kidney disease
(NIH/National Institute of Diabetes and Digestive and Kidney Diseases) Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 15, 2014 Category: Global & Universal Source Type: news
Kadmon begins Phase IIa Portion of KD020 study
Kadmon has started the Phase IIa portion of a Phase Ib/IIa study of KD020 in autosomal dominant polycystic kidney disease (ADPKD), following unanimous recommendation of the study's data safety committee. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2014 Category: Pharmaceuticals Source Type: news
European ADPKD forum launches
The European ADPKD Forum (EAF) has been created, which is a new multidisciplinary group of leading medical and patient group experts dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 2, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Nephrology Autosomal dominant polycystic kidney disease genetic kidney disease Latest News multidisciplinary expert group Source Type: news
